Abstract
An updated review of antiplatelet therapy in acute coronary syndrome: the roles of aspirin and thienopyridines (ticlopidine, clopidogrel); the benefit of aspirin-clopidogrel combination shown in the CURE and CLARITY-TIMI 28 trials; and three new approaches to overcome the limitations of clopidogrel: doubling the clopidogrel loading dose (reducing cardiovascular events in patients undergoing PCI but increasing major bleeding), switching to prasugrel (reducing cardiovascular events but increasing major bleeding) and switching to ticagrelor (reducing all-cause mortality and cardiovascular events without increasing major bleeding). (The article has no abstract; this summary was written briefly from the introduction and conclusion.)